ArchiveNovember 2020

Understanding cladribine. ChariotMS

As you know ProfK is a CLAD lad and we are gearing up to start ChariotMS with us going to use oral cladribine. Today I give you a link (See below) to a review on cladribine and as a COI The content has nothing to do with me. If you are considering the trial, make a cup of tea and you can read it for the next few minutes. Hope it doesn’t act as a sleeping tablet, as it is quite long. But it...

Control of Fatigue a Placebo effect?

A cross-over trial of 3 different fatigue drugs showed no difference from the fake treatment. Maybe ProfG wil comment on this, but it shows why trials are done Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue...

Anti-drug antibody awareness: HCP survey

Hello, my name is Farhana and I am a third year Biomedical Sciences student at Queen Mary University of London. I was born and brought up in Rome and moved to the UK when I was 12 where I completed my GCSE and A-Levels. After completing my degree, I am hoping to study medicine and become a doctor specialising in neuroscience or paediatrics. I am hoping work around the world as my ambition to...

If you want to get rid of EBV maybe time to look at CAR-T

This is one for the hard-core scientisty types, but you ask about how to get rid of EBV. Here is a type of vaccination. You engineer T cells tonget rid of EBV. This is a mouse study but the CAR-T technology can and has been used in humans CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease.Slabik C, Kalbarczyk M...

Not being treated is a risk factor for secondary progressive MS

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.Iaffaldano P, Lucisano G, Patti F, Brescia Morra V, De Luca G, Lugaresi A, Zaffaroni M, Inglese M, Salemi G, Cocco E, Conte A, Ferraro D, Galgani S, Bergamaschi R, Pozzilli C, Salvetti M, Lus G, Rovaris M, Maniscalco GT, Logullo FO, Paolicelli D, Achille M, Marrazzo G, Lovato V, Comi...

ProfK launched ChariotMS last week. Case reports of COVID-cladribine

There has not been as much information about COVID-19 and oral cladribine as has occurred with anti-CD20. In view of the launch of ChariotMS by ProfK. This case report is welcome news in that both people who developed COVID were not hosptialised and recovered. They were relatively young and may be expected to recover but the fact that they had COVID shortly after treatment when the depleting...

#MSCOVID19 Viral Vaccines

We have heard about the RNA vaccines and today MEDCRAM (118) will tell you about the Oxford/Astrazeneca Vaccine. This is the vaccine that the UK has purchased the most of. I think it is unlikely that it will be offered to people on immunosuppressive DMT, although it is replication deficient and so should not be able to cause an infection. This week we had a nice email from Dr Seheult “Dear...

The ugly fruit

There is overwhelming public interest to support COVID-19 vaccine development. In fact many have already done this. As the UK gears up to participate in its third vaccine study called ENSEMBLE, a Phase 3 clinical trial with the Janssen developed Ad26-vectored vaccine candidate shortly with participants drawn from the NHS vaccines registry, the lack of transparent participant information is...

#MSCOVID19 Antibodies

casirivimab and imdevimab, bamlanivimab If you live in the USA the FDA has given emergency approval for two antibodies (one a cocktail of two antibodies 1.2g cashirivimab and imdevimab 1.2g) and the other a single 0.7g antibody (Bamlanivimab) available for the old age people likely to become severe to reduce the chance of hospitalization. It is not approved for severely affected people who are...

Translate

Categories

Recent Posts

Recent Comments

Archives